Technical Analysis for CERE - Cerevel Therapeutics Holdings, Inc.

Grade Last Price % Change Price Change
C 42.27 -0.26% -0.11
CERE closed down 0.26 percent on Thursday, March 28, 2024, on 69 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
Gilligan's Island Sell Setup Bearish Swing Setup 2.77%
New 52 Week Closing High Bullish 2.77%
Pocket Pivot Bullish Swing Setup 2.77%
Volume Surge Other 2.77%
Calm After Storm Range Contraction 2.77%
Narrow Range Bar Range Contraction 2.77%
New 52 Week High Strength 2.77%
Parabolic Rise Strength 2.77%
Upper Bollinger Band Walk Strength 2.77%
New 52 Week Closing High Bullish 14.46%

   Recent Intraday Alerts

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cerevel Therapeutics Holdings, Inc. Description

Cerevel Therapeutics Holdings, Inc. operates as a clinical-stage biopharmaceutical company engages in the development of various therapies for neuroscience diseases. Its products include CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase 1b multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase 2 proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase 1 proof-of-principle trials in acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase 3 program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase 1 single ascending dose trials for the treatment of substance use disorder (SUD). It is also involved in the development of various preclinical compounds for various neuroscience indications. The company was founded in 2018 and is headquartered in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Neuroscience Schizophrenia Dementia Epilepsy Seizure Medicinal Chemistry Dopamine Substance Use Disorder Taar1 Agonists

Is CERE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 43.5898
52 Week Low 19.59
Average Volume 1,521,057
200-Day Moving Average 31.90
50-Day Moving Average 41.92
20-Day Moving Average 41.91
10-Day Moving Average 42.34
Average True Range 0.36
RSI (14) 57.81
ADX 21.94
+DI 22.30
-DI 16.56
Chandelier Exit (Long, 3 ATRs) 41.71
Chandelier Exit (Short, 3 ATRs) 41.88
Upper Bollinger Bands 42.96
Lower Bollinger Band 40.87
Percent B (%b) 0.67
BandWidth 5.00
MACD Line 0.22
MACD Signal Line 0.19
MACD Histogram 0.0291
Fundamentals Value
Market Cap 7.67 Billion
Num Shares 181 Million
EPS -2.50
Price-to-Earnings (P/E) Ratio -16.91
Price-to-Sales 0.00
Price-to-Book 28.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.68
Resistance 3 (R3) 42.67 42.52 42.61
Resistance 2 (R2) 42.52 42.42 42.53 42.58
Resistance 1 (R1) 42.40 42.36 42.33 42.41 42.56
Pivot Point 42.25 42.25 42.22 42.26 42.25
Support 1 (S1) 42.13 42.15 42.06 42.14 41.98
Support 2 (S2) 41.98 42.09 41.99 41.96
Support 3 (S3) 41.86 41.98 41.93
Support 4 (S4) 41.87